Universal reference book for medicines
Product name: DEXAPOS ® (DEXAPOS ® )

Active substance: dexamethasone

Type: GCS for topical application in ophthalmology

Manufacturer: URSAPHARM Arzneimittel (Germany)
Composition, form of production and packaging
Eye drops 0.1%
colorless, transparent.

1 ml

Dexamethasone 21-Sulfobenzoate 1 mg

Excipients: methylhydroxypropylcellulose, dextrose, thiomersal (thimerosal), water d / u.

5 ml - a bottle-droppers polyethylene (1) - packs cardboard.


The product description was approved by the manufacturer for the 2009 print edition.


GCS for topical application in ophthalmology.
Has anti-inflammatory, anti-allergic and anti-exsudative effect.
Active substance dexapos - dexamethasone - stabilizes the cell membranes, reduces the permeability of capillaries, causes an antiexudative effect, stabilizing the membranes of lysosomes.
It has antiproliferative and immunosuppressive activity. Inhibits the expression of genes encoding the synthesis of proteins involved in the development of inflammation. The anti-inflammatory and antiallergic effect of dexamethasone is 25 times that of cortisol, which is a natural endogenous SCS.
The methylhydroxypropylcellulose included in the dexapos as an auxiliary component contributes to the long-term retention of the active substance on the anterior surface of the eye, thereby increasing the efficacy and duration of action of the preparation.

With topical application, systemic absorption is low.


Dexamethasone penetrates through the cornea with intact epithelium into the moisture of the anterior chamber of the eye.

In the case of inflammation of the eye or damage to the mucous membrane and cornea, the rate of penetration of dexamethasone significantly increases.

With topical application, systemic absorption is low.


Acute and chronic inflammatory processes:

- conjunctivitis;

- sclerite;

- Deep keratitis without epithelial damage;

- irit;

- Iridocyclitis;

- Choroiditis;

- chorioretinitis;

- sympathetic ophthalmia.

Allergic eye diseases:

- allergic conjunctivitis;

- allergic keratoconjunctivitis;

- Pollinosis.

Prevention and treatment of inflammatory phenomena in the postoperative and post-traumatic period.


Eye drops are instilled in the conjunctival sac by 1-2 drops 3-5 times / day.

The duration of therapy should not exceed 2-3 weeks.

The decision on the duration of the course of treatment is based on the effectiveness of the drug, the severity of the symptoms, the likelihood of developing side effects.


From the side of the organ of vision: burning sensation (occurs immediately after instillation and quickly passes);
with prolonged use - the development of secondary glaucoma, steroid cataracts.

- keratitis caused by Herpes simplex or Varicella zoster (dendritic keratitis);

- viral lesions of the cornea and conjunctiva (including with chicken pox);

- mycobacterial infections of the eyes;

- fungal diseases of the eyes;

- acute purulent diseases of the eyes with epithelial lesions of the cornea;

- corneal epitheliopathy;

- increased intraocular pressure;

- Hypersensitivity to the components of the drug.


Adequate and strictly controlled clinical trials of the safety of the use of the drug Dexapos during pregnancy and lactation were not conducted.

Destination Dexapos is only possible if the intended benefit of therapy for the mother exceeds the potential risk to the fetus or child.


To date, no clinical studies have been conducted on the safety and efficacy of the use of dexapos in children.
The use of the drug in pediatrics is possible if the expected therapeutic effect exceeds the potential risk of side effects.

If the duration of the drug is more than 2 weeks, as well as in patients with an indication of open and closed-angle glaucoma in a history, it is recommended to regularly monitor the intraocular pressure.

If the use of contact lenses is necessary, then they should be removed before instillation of the drug Dexapos and set again not earlier than 20 minutes.

The patient should be informed that if side effects occur, the treatment should be stopped immediately and referred to the ophthalmologist.

Use in Pediatrics

To date, no clinical studies have been conducted on the safety and efficacy of the use of dexapos in children.
The use of the drug in pediatrics is possible if the expected therapeutic effect exceeds the potential risk of side effects.
Impact on the ability to drive vehicles and manage mechanisms

Immediately after the use of the drug Dexapos, a short-term disturbance of visual acuity may occur, leading to a slowing of the psychomotor reactions.
Therefore, it is not recommended to apply the drug directly before working with mechanisms and driving vehicles.

When using Dexapos, an overdose is unlikely.


Drug interaction of the drug Dexapos is not described.


The drug is released by prescription.


List B. The drug should be stored out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
After opening the vial, the drug should be used within 6 weeks.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!